Prostate Cancer - Prostate cancer urine test identifies men who can safely avoid immediate treatment
Can't see this email? View it online
   
  Prostate Cancer  
  The latest prostate cancer news from News Medical  
 

Understanding  the current medical landscape of prostate cancer Understanding the current medical landscape of prostate cancer

In this interview, News-Medical talks to Dr. Simon Chowdhury, Consultant Medical Oncologist, and Laetitia Decroix Guilloux, Vice President, EMEA Commercial Strategy Lead at Janssen Oncology, to discuss the unmet needs in prostate cancer, scientific advancements, and Janssen’s heritage in the disease area.

Read the full interview now
 
   Prostate cancer urine test identifies men who can safely avoid immediate treatmentProstate cancer urine test identifies men who can safely avoid immediate treatment
 
Researchers at the University of East Anglia have shown that a prostate cancer urine test can identify men at 'intermediate risk' who can safely avoid immediate treatment and benefit from 'active surveillance' instead.
 
   Genetic biomarker test predicts how men with high-risk prostate cancer will respond to treatmentGenetic biomarker test predicts how men with high-risk prostate cancer will respond to treatment
 
A new meta-analysis finds that a genetic biomarker test accurately predicts how men with high-risk prostate cancer will respond to treatment with radiation and hormone therapy.
 
 Study finds 24% higher prostate cancer risk among rescue/recovery workers after World Trade Center attacks
 
Study finds 24% higher prostate cancer risk among rescue/recovery workers after World Trade Center attacksThe risk of prostate cancer was 24% higher among 9/11 rescue and recovery workers after the attacks on the World Trade Center in 2001, with the highest risk among the earliest responders, finds research published online in the journal Occupational & Environmental Medicine.
 
 
 Genetic biomarker test could help personalize therapy for men with high-risk prostate cancer
 
Genetic biomarker test could help personalize therapy for men with high-risk prostate cancerA new meta-analysis finds that a genetic biomarker test accurately predicts how men with high-risk prostate cancer will respond to treatment with radiation and hormone therapy.
 
 
 Study provides new data on discontinuation of active surveillance by low-risk prostate cancer patients
 
Study provides new data on discontinuation of active surveillance by low-risk prostate cancer patientsNearly half of men initially managed with active surveillance for "low-risk" prostate cancer transition to definitive treatment – such as surgery or radiation therapy – within a few years after diagnosis.
 
 
 Tumor-related risk factors affect conversion of active surveillance to treatment for prostate cancer
 
Tumor-related risk factors affect conversion of active surveillance to treatment for prostate cancerFor men with "low-risk" prostate cancer initially managed with active surveillance, cancer-related factors such as tumor grade and size are key risk factors for conversion to active treatment, reports a study in The Journal of Urology®, an Official Journal of the American Urological Association.
 
 
 Patients with enlarged prostate may have lower chances of significant prostate cancer
 
Patients with enlarged prostate may have lower chances of significant prostate cancerA team of Beaumont Health researchers from Radiology, Radiation Oncology and Urology studied the relationship between benign prostatic hyperplasia, or BPH, and prostate cancer in 405 men by quantitatively looking at different parts of prostate tissue on MRI.
 
 
 Cardiovascular safety of prostate cancer treatments remains unresolved
 
Cardiovascular safety of prostate cancer treatments remains unresolvedThe relative cardiovascular safety of different types of androgen deprivation therapy (ADT) for prostate cancer remains unresolved after the PRONOUNCE trial was terminated early. The late breaking research is presented in a Hot Line session today at ESC Congress 2021.